Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Approval after phase I: ceritinib runs the three-minute mile.

Approval after phase I: ceritinib runs the three-minute mile. Oncologist. 2014 Jun; 19(6):577-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.